Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
Adolescent
Adult
Albumins
/ analysis
Algorithms
Antibodies, Anti-Idiotypic
Antibodies, Blocking
/ cerebrospinal fluid
Antibody Specificity
Aquaporin 4
/ cerebrospinal fluid
Blood-Brain Barrier
/ pathology
Child
Female
Humans
Immunoglobulin G
/ cerebrospinal fluid
Male
Middle Aged
Myelin-Oligodendrocyte Glycoprotein
/ cerebrospinal fluid
Neuromyelitis Optica
/ cerebrospinal fluid
Spinal Cord
/ immunology
Young Adult
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
06 07 2021
06 07 2021
Historique:
received:
13
11
2020
accepted:
22
03
2021
pubmed:
14
5
2021
medline:
24
7
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
To elucidate the differences in the source and in the level of intrathecal synthesis between anti-aquaporin-4 antibodies (AQP4-IgG) and anti-myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). Thirty-eight patients with MOG-IgG-associated disease and 36 with AQP4-IgG-positive neuromyelitis optica spectrum disorders (NMOSD) were studied for the antibody titers in the sera and CSF simultaneously collected in the acute attacks. The quotients between CSF and serum levels of albumin, total immunoglobulin G, and each disease-specific antibody were calculated. Intrathecal production level in each disease-specific antibody was evaluated by calculating the antibody index from these quotients. Eleven of the 38 patients with MOG-IgG were positive for the antibody only in the CSF, while no patient with AQP4-IgG showed CSF-restricted AQP4-IgG. Blood-brain barrier compromise as shown by raised albumin quotients was seen in 75.0% of MOG-IgG-positive cases and 43.8% of AQP4-IgG-positive cases. Moreover, MOG-IgG quotients were >10 times higher than AQP4-IgG quotients (effect size Intrathecal production of MOG-IgG may occur more frequently than that of AQP4-IgG. This finding implies the different properties of B-cell trafficking and antibody production between MOG-IgG-associated disease and AQP4-IgG-positive NMOSD.
Identifiants
pubmed: 33980704
pii: WNL.0000000000012175
doi: 10.1212/WNL.0000000000012175
pmc: PMC8312856
doi:
Substances chimiques
AQP4 protein, human
0
Albumins
0
Antibodies, Anti-Idiotypic
0
Antibodies, Blocking
0
Aquaporin 4
0
Immunoglobulin G
0
MOG protein, human
0
Myelin-Oligodendrocyte Glycoprotein
0
anti-IgG
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1-e12Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Neuroimmunol. 2016 Oct 15;299:152-157
pubmed: 27725114
Front Neurol. 2018 Oct 23;9:888
pubmed: 30405519
Front Immunol. 2017 May 08;8:529
pubmed: 28533781
Ann Neurol. 2014 Aug;76(2):305-9
pubmed: 24977390
Clin Chem Lab Med. 2001 Apr;39(4):324-32
pubmed: 11388657
J Neurol. 2017 Dec;264(12):2420-2430
pubmed: 29063242
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):100
pubmed: 31773369
Clin Pharmacokinet. 2010 Aug;49(8):493-507
pubmed: 20608753
J Neuroinflammation. 2010 Sep 08;7:52
pubmed: 20825655
Histochem Cell Biol. 1995 Jul;104(1):1-9
pubmed: 7584554
Channels (Austin). 2007 Jan-Feb;1(1):29-38
pubmed: 19170255
Mult Scler Relat Disord. 2019 Feb;28:165-166
pubmed: 30605793
Clin Chem. 1991 Jul;37(7):1153-60
pubmed: 1855284
Ann N Y Acad Sci. 2016 Feb;1366(1):20-39
pubmed: 26096370
Arch Neurol. 2010 Sep;67(9):1102-8
pubmed: 20837855
Front Neurol. 2020 Jun 26;11:501
pubmed: 32670177
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 17;7(3):
pubmed: 32184342
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
J Neuroinflammation. 2020 Sep 3;17(1):261
pubmed: 32883348
Mult Scler J Exp Transl Clin. 2018 Jul 17;4(3):2055217318787829
pubmed: 30038790
Ann Neurol. 2009 Nov;66(5):617-29
pubmed: 19938104
Mult Scler Relat Disord. 2020 Oct;45:102399
pubmed: 32702642
Brain. 2007 May;130(Pt 5):1235-43
pubmed: 17449477
PLoS One. 2013 Dec 10;8(12):e83036
pubmed: 24340077
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(2):e81
pubmed: 25798445
J Neurol Sci. 2019 Jan 15;396:225-231
pubmed: 30522039
Pract Neurol. 2019 Jun;19(3):187-195
pubmed: 30530724
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Tohoku J Exp Med. 2006 Dec;210(4):307-13
pubmed: 17146196
Fluids Barriers CNS. 2012 Jul 31;9(1):14
pubmed: 22849518
J Ophthalmol. 2019 Apr 01;2019:4015075
pubmed: 31061727
JAMA Neurol. 2014 Mar;71(3):276-83
pubmed: 24425068
Ann Clin Transl Neurol. 2017 May 09;4(6):369-380
pubmed: 28589164
Arq Neuropsiquiatr. 2016 Jun;74(6):501-12
pubmed: 27332077
Neurology. 2019 Nov 12;93(20):e1867-e1872
pubmed: 31645473
J Clin Pharmacol. 2012 Aug;52(8):1150-61
pubmed: 21947370
Acta Neuropathol. 2020 May;139(5):875-892
pubmed: 32048003
J Exp Med. 2005 Aug 15;202(4):473-7
pubmed: 16087714
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
JAMA Netw Open. 2019 Oct 2;2(10):e1912732
pubmed: 31596489
Mult Scler Int. 2015;2015:296184
pubmed: 25653878
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
J Neuroinflammation. 2019 Jul 2;16(1):134
pubmed: 31266527
Front Neurol. 2020 Sep 09;11:960
pubmed: 33013639
Am J Trop Med Hyg. 2010 Jun;82(6):1094-8
pubmed: 20519605
Mult Scler Relat Disord. 2020 Oct;45:102382
pubmed: 32674030